Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Reiterated by Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They currently have a $115.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 154.54% from the company’s current price.

A number of other research analysts also recently commented on the company. Wedbush reaffirmed a “neutral” rating and issued a $45.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Thursday, July 18th. Robert W. Baird boosted their price target on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. The Goldman Sachs Group raised Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and boosted their price target for the company from $56.00 to $67.00 in a research note on Thursday, June 6th. Bank of America dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating for the company in a research note on Friday, May 31st. Finally, TD Cowen boosted their price target on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.50.

Ultragenyx Pharmaceutical Stock Up 1.6 %

RARE stock opened at $45.18 on Monday. The company has a fifty day moving average price of $41.20 and a two-hundred day moving average price of $44.54. Ultragenyx Pharmaceutical has a one year low of $31.52 and a one year high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The business had revenue of $108.83 million during the quarter, compared to the consensus estimate of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The company’s revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.33) EPS. Research analysts forecast that Ultragenyx Pharmaceutical will post -6.45 EPS for the current year.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 9,806 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the sale, the executive vice president now directly owns 57,981 shares in the company, valued at $2,609,145. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.10, for a total transaction of $71,390.70. Following the transaction, the director now directly owns 7,248 shares in the company, valued at approximately $297,892.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 9,806 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the transaction, the executive vice president now owns 57,981 shares in the company, valued at $2,609,145. The disclosure for this sale can be found here. Insiders sold 12,127 shares of company stock valued at $536,593 over the last quarter. 5.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Sands Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 59.8% during the 4th quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock valued at $196,923,000 after purchasing an additional 1,540,791 shares in the last quarter. RTW Investments LP increased its holdings in Ultragenyx Pharmaceutical by 27.4% during the 4th quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock worth $329,340,000 after purchasing an additional 1,481,997 shares in the last quarter. Vanguard Group Inc. grew its holdings in Ultragenyx Pharmaceutical by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 8,673,432 shares of the biopharmaceutical company’s stock worth $414,764,000 after buying an additional 1,440,264 shares in the last quarter. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $36,846,000. Finally, Avoro Capital Advisors LLC grew its position in Ultragenyx Pharmaceutical by 137.1% in the 1st quarter. Avoro Capital Advisors LLC now owns 830,000 shares of the biopharmaceutical company’s stock worth $38,753,000 after purchasing an additional 480,000 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.